Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025)
Quarterly Total Non-Current Liabilities rose 14.84% to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, up 14.84% year-over-year, with the annual reading at $23.4 million for FY2025, 14.84% up from the prior year.
Tyra Biosciences filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $23.4 million for Q4 2025.
- Total Non-Current Liabilities hit $23.4 million in Q4 2025 for Tyra Biosciences, up from $21.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $23.4 million in Q4 2025 and bottomed at $4.6 million in Q4 2021.
- Average Total Non-Current Liabilities over 5 years is $14.0 million, with a median of $15.5 million recorded in 2023.
- Peak annual rise in Total Non-Current Liabilities hit 163.34% in 2023, while the deepest fall reached 18.15% in 2023.
- Tyra Biosciences' Total Non-Current Liabilities stood at $4.6 million in 2021, then soared by 78.01% to $8.2 million in 2022, then soared by 163.34% to $21.5 million in 2023, then decreased by 5.31% to $20.4 million in 2024, then grew by 14.84% to $23.4 million in 2025.
- Per Business Quant, the three most recent readings for TYRA's Total Non-Current Liabilities are $23.4 million (Q4 2025), $21.3 million (Q3 2025), and $19.4 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.43 Mn |
| Sep 30, 2025 | 21.34 Mn |
| Jun 30, 2025 | 19.35 Mn |
| Mar 31, 2025 | 19.94 Mn |
| Dec 31, 2024 | 20.40 Mn |
| Sep 30, 2024 | 18.29 Mn |
| Jun 30, 2024 | 16.40 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Dec 31, 2023 | 21.55 Mn |
| Sep 30, 2023 | 16.11 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 6.13 Mn |
| Dec 31, 2022 | 8.18 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 4.60 Mn |
| Sep 30, 2021 | 5.81 Mn |
| Dec 31, 2020 | 1.86 Mn |